Selective Serotonin Reuptake Inhibitors (SSRIs): Past Present and Future
|
Edited By:S. Clare StanfordUniversity College - London ISBN: 978-1-57059-649-0 Published: 1999-12-01 |
The SSRIs have had a major impact on the treatment of depression and one, Prozac, has even attained cult status. Yet, their predecessors are still used with impunity and we have no definitive explanation for their therapeutic effects. In reviewing the established and novel indications for treatment with these drugs, SSRIs: Past, Present and Future, incorporates a frank and detailed appraisal of their safety, efficacy and tolerability as well as exploring their underlying neurobiology.
Chapters available from this book
SSRIs: Where Now, Where Next?
David J. Heal and Sharon C. Cheetham
It is interesting to note that in the title of their review on fluoxetine (`Prozac',Lilly), Wong, Bymaster and Engleman1 describe this drug as "the first selective serotonin re-uptake inhibitor." Like much of the subject, this claim owes rather more to perpetuatin...
The Mechanism of Action of SSRIs:A New Hypothesis
Lori L. Davis, Kimberly A. Yonkers, Madhukar Trivedi, Gerald L.Kramer and Frederick Petty
The introduction of the selective serotonin reuptake inhibitors (SSRIs) into medical treatment in the 1980s revolutionized psychiatric practice and fueled the interest in the role of serotonin (5-hydroxytryptamine, 5-HT) in the underlying neurobiology of the psychiatric disorders. In ...
SSRI-Induced Changes in Catecholaminergic Transmission
S. Clare Stanford
The selective serotonin reuptake inhibitors (SSRIs) are a chemically diverse group of compounds which share the characteristic of potently inhibiting neuronal reuptake of serotonin (5-hydroxytryptamine, 5-HT). As their name suggests, the antidepressant effects of SSRIs are widely attribu...
SSRI-Induced Functional Changes in Serotonergic Neurons
Ildefonso Hervás, Andreu Raurich, Luz Romero, Roser Cortés and Francesc Artigas
The term `SSRIs' encompasses several chemical agents that have in common their ability to inhibit selectively the function of the serotonin (5-hydroxytryptamine, 5-HT) transporter. This is located on the membranes of serotonergic and glial cells of the brain and other cells outside the c...
Mechanism of Action of Different Classes of Antidepressants: Evidence from 5-HT Challenge Studies
Ian M. Anderson and Christopher Mortimore
The discovery in the 1950s that imipramine and iproniazid had antidepressant properties was soon followed by the recognition that they acted on monoamine systems. This laid the foundation for two interrelated but logically distinct theories which have dominated biological research int...
SSRIs and Suicide
John A. Henry and Carol A. Rivas
The selective serotonin reuptake inhibitors (SSRIs) have increased in popularity and extent of use since their introduction. At the same time, our knowledge concerning the relationship between suicide and depression has increased. The impact of this group of drugs on this knowledge has b...
SSRIs and Sexual Function
Peter A. Sargent and Guy M. Goodwin
Human sexual dysfunction is described in ICD-101 under broad categories, reflecting the pragmatic division of the normal sexual response, into phases of desire, arousal, orgasm and resolution:
SSRIs, Drug Withdrawal and Abuse: Problem or Treatment?
C. Heather Ashton and Allan H. Young
Selective serotonin reuptake inhibitors (SSRIs) have considerable advantages over earlier antidepressants, such as most tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs), but like all drugs they also have adverse effects. Advantages of SSRIs include: greater to...
SSRIs and Patient Groups with Specific Treatment Problems
John Hughes, Brian Lunn and John O'Brien
Selective serotonin reuptake inhibitors (SSRIs), whilst initially launched solely as anti- depressants, have been used increasingly as treatments for other disorders and in patients who are vulnerable to the adverse effects of other antidepressants. This chapter examines the role of SSRI...
SSRIs in Depression: Distinctive Actions?
Julie Newman and Andrew A. Nierenberg
The introduction of the selective serotonin reuptake inhibitors (SSRIs) has radically changed the treatment of depression worldwide. The five currently marketed SSRIs, fluoxetine, sertraline, paroxetine, fluvoxamine and citalopram were accepted by international regulatory agencies becaus...
Clinical Pharmacokinetics of SSRIs
Pierre Baumann, Chin B Eap and Pierre Voirol
Citalopram,1 fluoxetine,2,3 fluvoxamine,4 paroxetine5 and sertraline6 are the five anti- depressants which are known as selective serotonin reuptake inhibitors (SSRIs) (Fig. 2.1). Their clinical efficacy, good tol...
The Discovery of The SSRIs: A Milestone In Neuropsychopharmacology and Rational Drug Design
Arvid Carlsson
Besides being a major therapeutic advance, the selective serotonin reuptake inhibitors (SSRIs) have become important tools in basic and clinical brain research. They were the first drugs to establish beyond doubt a pathophysiological role for serotonin (5-HT) in affective illnesses an...
